235 related articles for article (PubMed ID: 34936380)
1. A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia.
Zhang Q; Hresko ME; Picton LK; Su L; Hollander MJ; Nunez-Cruz S; Zhang Z; Assenmacher CA; Sockolosky JT; Garcia KC; Milone MC
Sci Transl Med; 2021 Dec; 13(625):eabg6986. PubMed ID: 34936380
[TBL] [Abstract][Full Text] [Related]
2. An orthogonal IL-2 and IL-2Rβ system drives persistence and activation of CAR T cells and clearance of bulky lymphoma.
Aspuria PJ; Vivona S; Bauer M; Semana M; Ratti N; McCauley S; Riener R; de Waal Malefyt R; Rokkam D; Emmerich J; Kastelein RA; Lupardus PJ; Oft M
Sci Transl Med; 2021 Dec; 13(625):eabg7565. PubMed ID: 34936383
[TBL] [Abstract][Full Text] [Related]
3. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
5. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells.
Jiang Z; Liao R; Lv J; Li S; Zheng D; Qin L; Wu D; Chen S; Long Y; Wu Q; Wang S; Lin S; Huang X; Tang Z; Shi P; Zhou H; Liu Q; Zhao R; Li Y; Jie Y; Wei W; Lai P; Du X; Cui S; Weinkove R; Liu P; Pei D; Yao Y; Li P
Leukemia; 2021 May; 35(5):1380-1391. PubMed ID: 33168950
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
8. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
9. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
11. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
12. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
14. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
15. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
Pegram HJ; Purdon TJ; van Leeuwen DG; Curran KJ; Giralt SA; Barker JN; Brentjens RJ
Leukemia; 2015 Feb; 29(2):415-22. PubMed ID: 25005243
[TBL] [Abstract][Full Text] [Related]
16. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
[TBL] [Abstract][Full Text] [Related]
17. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
[TBL] [Abstract][Full Text] [Related]
18. Reducing
Ghassemi S; Nunez-Cruz S; O'Connor RS; Fraietta JA; Patel PR; Scholler J; Barrett DM; Lundh SM; Davis MM; Bedoya F; Zhang C; Leferovich J; Lacey SF; Levine BL; Grupp SA; June CH; Melenhorst JJ; Milone MC
Cancer Immunol Res; 2018 Sep; 6(9):1100-1109. PubMed ID: 30030295
[TBL] [Abstract][Full Text] [Related]
19. Versatile strategy for controlling the specificity and activity of engineered T cells.
Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
[TBL] [Abstract][Full Text] [Related]
20. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
